Brazil has just opened a regulatory fast-track for AI medical devices, promising market approval in just 90 days. This is a massive opportunity for MedTech companies looking to expand into Latin America, but a hidden challenge is causing significant delays and unexpected costs for even the most prepared firms.

This episode of MedTech Global Insights unpacks ANVISA's new resolution. We reveal the stringent, often overlooked post-market surveillance and data privacy rules that are tied to this accelerated pathway. Learn why early excitement can quickly turn into a compliance nightmare if you're not prepared for the local requirements that go far beyond standard FDA or EU expectations.

For instance, a German AI diagnostics company celebrated its record-fast 85-day approval in Brazil. Their victory quickly soured when they were hit with a surprise audit of their data privacy protocols and algorithm monitoring systems, requirements they were completely unprepared for. Their product launch is now stalled by at least six months, a costly lesson in the importance of local expertise.

Key Takeaways This Episode:

- Why is ANVISA's new fast-track for AI software a double-edged sword?

- What are the critical post-market surveillance rules in Brazil that most foreign companies miss?

- How can your existing FDA or CE documentation create unexpected problems in your Brazilian submission?

- What specific data privacy clauses in Brazil's LGPD law are tripping up MedTech firms?

- Is it possible to centralize your regulatory strategy for multiple Latin American markets?

- How do you select a local representative in Brazil who truly understands AI-specific regulations?

- What are the hidden costs associated with Brazil's new data localization requirements for medical devices?

To navigate these complex challenges, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and access to our global medical device database, visit https://pureglobal.ai/.